DOCSLIB.ORG

In Vitro Evaluation for Antidandruff Activity of Selected Homoeopathic Medicines Against Pityrosporum Ovale”

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
In Vitro Evaluation for Antidandruff Activity of Selected Homoeopathic Medicines Against Pityrosporum Ovale” [ VOLUME 5 I ISSUE 3 I JULY– SEPT 2018] E ISSN 2348 –1269, PRINT ISSN 2349-5138 “IN VITRO EVALUATION FOR ANTIDANDRUFF ACTIVITY OF SELECTED HOMOEOPATHIC MEDICINES AGAINST PITYROSPORUM OVALE” Chetan Hanamantrao Shinde1, Vidhi Sarin2, Pashmin Kaur Anand2, Bipinraj Nirichan Kunchiraman3 & Arun Bhargav Jadhav4 1Associate Professor, Department of Homoeopathic Pharmacy, Homoeopathic Medical College & Hospital, Bharati Vidyapeeth Deemed To Be University, Pune, India. 2 Department of Microbiology, Rajiv Gandhi Institute of Information Technology and Biotechnology, Bharati Vidyapeeth Deemed To Be University, Pune, India. 3Assistant Professor, Department of Microbiology, Rajiv Gandhi Institute of Information Technology and Biotechnology, Bharati Vidyapeeth Deemed To Be University, Pune, India. 4Principal, Bharati Vidyapeeth (Deemed to be) University,, Homoeopathic Medical College and Hospital, Katraj - Dhankawadi, Pune - 411043. Received: June 06, 2018 Accepted: July 22, 2018 ABSTRACT Recently there is an increase in the number of patients affected by recurring dandruff due to the development of antifungal resistance in pathogenic dandruff species. Current study has aimed to screen various homoeopathic medicines and their potencies for inhibition of Pityrosporum ovale. The homoeopathic medicines Azadirachta indica, Cinchona officinalis, Zincum metallicum, Iodium, Selenium, Sulphur, Acidum Benzoicum, Phosphorus, Acidum Sulphuricum and Zingiber officinale in 6C, 12C, 30C, 200C, 1M potencies were screened by tube assay method using Potato Dextrose Broth and found out that Acidum Benzoicum 6C, Cinchona officinalis 6C, Sulphur 6C, Zingiber officinale 6C, Acidum Sulphuricum 12C, Azadirachta indica 12C, Phosphorus 12C, Selenium 12C, Iodium 30C and Zincum Metallicum 200C could inhibit Pityrosporum ovale (MTCC-1374). Keywords: Anti-dandruff, homoeopathic medicines, Acidum Sulphuricum, Acidum Benzoicum, Azadirachta indica, Cinchona officinalis, Iodium, Phosphorus, Selenium, Sulphur, Zincum Metallicum, Zingiber officinale. INTRODUCTION Dandruff is a one of the common skin condition affecting scalp, generally caused by lipophilic yeast Malassezia (earlier known as Pityrosporum ovale) [Bergbrant IM, 1991], irrespective of region, age and sex. It is characterized by white dry flaky scales on the scalp and other intertriginous area (Rudramurthy S M et al, 2014). It is a very common condition and affects more than 50% of the world population. Since it affects the elegance and causes itching people around the world are on a lookout for effective dandruff controlling agent. In India, two species have been identified so far, M. restricta and M. furfur. There are many drugs such as chloroxine, ciclopirox, clobetasol, ketoconazole, salicylic acid, selenium sulfide, sulfur, tar and zinc pyrithione are available to treat dandruff (Ranganathan S and Mukhopadhyay T (2010), however, hardly any formulation have proven complete preventive and curative effect. Moreover, these drugs are reported to have various side effects (Tiwari1 A K, et al, 2011). As a result, scientists worldwide are looking for a new medicine or combination that can effectively control the pathogen and dandruff. Another approach is to identify medicines used in alternative medicine such as Homoeopathy. These medicines may play a significant role in treatment of dandruff without imparting any side effects. Homoeopathy offers constructive treatment of fungal infections particularly for Dandruff. Acidum Sulphuricum, Acidum Benzoicum, Azadirachta Indica, Cinchona Officinalis, Iodium, Phosphorus, Selenium, Sulphur, Zincum Metallicum and Zingiber Officinale are group of medicines used to treat symptoms similar to Pityrosporum ovale (Malassezia furfur) infection according to Complete, Murphy’s and Synthesis Homoeopathic Repertory, but there is no clear cut study regarding significant activity or mechanism of action (Zandvoort RV, 2003, Murphy R, 2014 and Schroyens F, 2014). Thus, it becomes imperative to collect, identify and validate the efficacy of Homoeopathic Medicines for management of dandruff. In the present study was aimed to screen the ability of various homeopathic medicines to inhibit pathogenic Pityrosporum ovale (Malassezia furfur) in-vitro and to study mechanism of inhibition. MATERIALS AND METHOD Media and Chemicals - All media was procured from Hi Media Mumbai, India. All the reagents and chemicals used in this work were of AR grade and procured from MERK India. 680헒 IJRAR- International Journal of Research and Analytical Reviews Research Paper [VOLUME 5 I ISSUE 3 I JULY – SEPT 2018] e ISSN 2348 –1269, Print ISSN 2349-5138 http://ijrar.com/ Cosmos Impact Factor 4.236 Homoeopathic Medicines preparation - Homoeopathic Medicines Acidum Sulphuricum, Acidum Benzoicum, Azadirachta indica, Cinchona officinalis, Iodium, Phosphorus, Selenium, Sulphur, Zincum Metallicum and Zingiber officinale were obtained from GMP approved Standard Homoeopathic Medicines Manufacturer in 6C, 12C, 30 C, 200 C, 1M liquid potencies. Organism – Pityrosporum ovale (MTCC-1374) was obtained from Microbial Type Culture Collection and Gene Bank, Institute of Microbial Technology, Chandigarh. It was maintained in potato dextrose agar slants containing corn oil and stored in refrigerator. For all studies dandruff cultures were grown in Potato dextrose broth containing corn oil and incubated at 25ºC for 72 h. Anti-dandruff assay Ant-dandruff activity of the medicines were determined using tube assay. Accordingly, fungal culture suspension (50µl) was inoculated on potato dextrose broth (650µl) with corn oil (100µl). Various potencies of the selected homoeopathic medicines (200µl) were added in each tube. It was followed by incubation at 25ºC for 72 h. Zinc Pyrithione (100µg/ml) was added as the positive control. Anti-fungal activity was scored by visual observation of the growth on the oil layer of media. MIC value MIC values of the selected medicines were found out using 96 well plate assay. Total volume in each well was adjusted to 100 µl with potato dextrose broth (30µl), varying potencies of homoeopathic medicines (50µl) and fungal culture (20µl, 0.5 OD). The experiment was conducted along with negative control (potato dextrose broth) and positive control (Zinc Pyrithione) and dispensing alcohol (ethanol 90%). Optical density of the culture was measured at zero hours and after 6 hrs. of incubation at 25ºC using Elisa plate reader (BIORAD) at 595 nm. The experiment was repeated three times and mean value was taken as the reading. Lysis studies for Dandruff For lysis study, the culture suspension (200µl) was mixed with 200µl of Homoeopathic medicines and incubated for 1 hr at 25ºC, after the incubation 50µl of the culture mixed with 50µl Trypan blue. The mixture was then loaded on a hemocytometer and observed under microscope to observe intact as well as lysed cells. Result Anti-dandruff screening and MIC. All homoeopathic medicines used were showed inhibition zone around well. The activity of the medicines varied for each potencies (Table.1). The MIC of the drug varied from 6C to 200C potencies as given in the Table 2. None of the tested medicine could induce cell lysis in the culture. Table 1. Anti dandruff activity of the Homoeopathic Medicines against Pityrosporum ovale Sr. Name of Homoeopathic 6C 12C 30C 200C 1M No. Medicine Extremely Extremely 1 Selenium + + + less less Extremely 2 Cinchona officinalis + Extremely less + ++ less Extremely 3 Azadiracta indica + Extremely less +++ ++ less Extremely Extremely 4 Phosphorus + Extremely less + less less Extremely Extremely Extremely 5 Acidum Benzoicum + Extremely less less less less 6 Zingiber + Extremely less + + + Extremely Extremely 7 Sulphur + + + less less Extremely Extremely 8 Acidum Sulphuricum + + + less less Extremely Extremely 9 Iodium + + + less less Research Paper IJRAR- International Journal of Research and Analytical Reviews 681헒 [ VOLUME 5 I ISSUE 3 I JULY– SEPT 2018] E ISSN 2348 –1269, PRINT ISSN 2349-5138 Extremely Extremely 10 Zincum metallicum + + + less less 11 Positive Control +++ 12 Negative control Extremely less Vehicle Control 13 ++ (Dispensing alcohol) Chemical Control 14 ++ (Zinc Pyrithione) Table 2. MIC of the Homoeopathic Medicines Sr. No. Medicine MIC value of (Homeopathic potency) 1 Azadirachta Indica 12C 2 Acidum Benzoicum 6C 3 Acidum Sulphuricum 12C 4 Cinchona officinalis 6C 5 Iodium 30C 6 Phosphorus 12C 7 Selenium 12C 8 Sulphur 6C 9 Zincum Metallicum 200C 10 Zingiber officinale 6C Discussion The aim of the current study was to screen the ability of homoeopathic medicines to inhibit Pityrosporum ovale (Malassezia furfur). The medicines were selected as per the Complete and Murphy’s Homoeopathic Repertory. The results of the screening study it was clear that selected medicines could inhibit Pityrosporum ovale (Malassezia furfur) in vitro, since they showed inhibition in tube assay. MIC value varied from 6C to 200C potencies. Pityrosporum ovale is a normal human skin flora associated with various skin conditions such as pityriasis versicolor, pityrosporum folliculitis, seborrhoeic dermatitis (dandruff) and some forms of atopic dermatitis. Formation of dandruff is a complex mechanism and the role lipophilic yeast such as Pityrosporum was widely accepted (Balows A, 1998 and Saint-Leger 1988). There are many anti-dandruff formulation available in the open market, most of them act as anti-fungals and can decrease the number of Pityrosporum yeast, However, consistent use of anti-dandruff treatment lose efficacy which might develop a resistant
Load more

Recommended publications
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0024365A1 Vaya Et Al
    US 2006.0024.365A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0024365A1 Vaya et al. (43) Pub. Date: Feb. 2, 2006 (54) NOVEL DOSAGE FORM (30) Foreign Application Priority Data (76) Inventors: Navin Vaya, Gujarat (IN); Rajesh Aug. 5, 2002 (IN)................................. 699/MUM/2002 Singh Karan, Gujarat (IN); Sunil Aug. 5, 2002 (IN). ... 697/MUM/2002 Sadanand, Gujarat (IN); Vinod Kumar Jan. 22, 2003 (IN)................................... 80/MUM/2003 Gupta, Gujarat (IN) Jan. 22, 2003 (IN)................................... 82/MUM/2003 Correspondence Address: Publication Classification HEDMAN & COSTIGAN P.C. (51) Int. Cl. 1185 AVENUE OF THE AMERICAS A6IK 9/22 (2006.01) NEW YORK, NY 10036 (US) (52) U.S. Cl. .............................................................. 424/468 (22) Filed: May 19, 2005 A dosage form comprising of a high dose, high Solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of Related U.S. Application Data immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of (63) Continuation-in-part of application No. 10/630,446, modified release active ingredient per unit is from 500 mg to filed on Jul. 29, 2003. 1500 mg, a process for preparing the dosage form. Patent Application Publication Feb. 2, 2006 Sheet 1 of 10 US 2006/0024.365A1 FIGURE 1 FIGURE 2 FIGURE 3 Patent Application Publication Feb. 2, 2006 Sheet 2 of 10 US 2006/0024.365A1 FIGURE 4 (a) 7 FIGURE 4 (b) Patent Application Publication Feb. 2, 2006 Sheet 3 of 10 US 2006/0024.365 A1 FIGURE 5 100 ov -- 60 40 20 C 2 4.
    [Show full text]
  • Multidrug Treatment with Nelfinavir and Cepharanthine Against COVID-19
    Supplemental Information Multidrug treatment with nelfinavir and cepharanthine against COVID-19 Hirofumi Ohashi1,2,¶, Koichi Watashi1,2,3,4*, Wakana Saso1,5.6,¶, Kaho Shionoya1,2, Shoya Iwanami7, Takatsugu Hirokawa8,9,10, Tsuyoshi Shirai11, Shigehiko Kanaya12, Yusuke Ito7, Kwang Su Kim7, Kazane Nishioka1,2, Shuji Ando13, Keisuke Ejima14, Yoshiki Koizumi15, Tomohiro Tanaka16, Shin Aoki16,17, Kouji Kuramochi2, Tadaki Suzuki18, Katsumi Maenaka19, Tetsuro Matano5,6, Masamichi Muramatsu1, Masayuki Saijo13, Kazuyuki Aihara20, Shingo Iwami4,7,21,22,23, Makoto Takeda24, Jane A. McKeating25, Takaji Wakita1 1Department of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan, 2Department of Applied Biological Science, Tokyo University of Science, Noda 278-8510, Japan, 3Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan, 4MIRAI, JST, Saitama 332-0012, Japan, 5The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan, 6AIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan, 7Department of Biology, Faculty of Sciences, Kyushu University, Fukuoka 812-8581, Japan, 8Cellular and Molecular Biotechnology Research Institute, National Institute of Advanced Industrial Science and Technology, Tokyo 135-0064, Japan, 9Division of Biomedical Science, Faculty of Medicine, University of Tsukuba, Tsukuba 305-8575, Japan, 10Transborder Medical Research Center, University of Tsukuba, Tsukuba 305-8575, Japan, 11Faculty of Bioscience, Nagahama Institute
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]
  • Pharmacy Program and Drug Formulary
    Pharmacy Program and Drug Formulary Secure Horizons Group Retiree Medicare Advantage Plan n Pharmacy Program Description n Platinum Plus Enhanced Formulary California Benefits Effective January 1, 2006 Table of Contents Your Secure Horizons Group Retiree Medicare Advantage Plan Prescription Drug Benefit........................................................................................................ iii Secure Horizons Pharmacy Program Definitions .................................................................... iii What Is the Platinum Plus Enhanced Formulary? ....................................................................iv Where to Have Your Prescriptions Filled .................................................................................iv Preferred and Non-Preferred Network Pharmacies .................................................................iv Network Preferred Pharmacy Locations ..................................................................................iv How to Fill a Prescription at a Network Pharmacy ...................................................................v Mail Service Pharmacy ..............................................................................................................v Secure Horizons Group Retiree Medicare Advantage Plan Offers a Two-Part Prescription Drug Benefit ..........................................................................vii Part 1 – Medicare Part D Prescription Drug Coverage ...................................................vii How Your Medicare
    [Show full text]
  • FORMULARY - Listed Alphabetically by BRAND Name Rev
    HMSA DRUG FORMULARY - Listed alphabetically by BRAND name Rev. 3/1/04 - Page 1 Ther. Generic Brand Select Select Choice Choice QUEST QUEST- CCS Child- Categ. Net ren's Code Code Footnote Code Footnote G = Generic. P = Preferred. O = Other brand. X = Covered. If a number appears next to alpha code, see last page for footnote text. 95 aripiprazole Abilify O O X 194 zafirlukast Accolate P 30 O X 30 56 quinapril Accupril O O 56 quinapril/ hctz Accuretic O O 241 isotretinoin Accutane O O 56 perindopril Aceon O O 11 glacial acetic acid Aci-jel O O 163 rabeprazole sodium Aciphex P P X 15 255 aclometasone dipropionate 0.05%, Aclovate O O cream/ ointment 167 ursodiol Actigall O O 261 masoprocol Actinex O O 122 estradiol/ norethindrone acetate Activella O O 152 risedronate Actonel P O X 146 pioglitazone Actos P O X 228 ketorolac tromethamine, ophthalmic Acular P O X 228 ketorolac tromethamine, ophthalmic Acular PF P O X 46 nifedipine Adalat O O 46 nifedipine, sustained release Adalat CC O O 62 amphetamine mixture Adderall P 8 O 8 X 8 X 8 62 amphetamine mixture, extended release Adderall XR P 7 O 7 X 7 X 7 190 salmeterol/ fluticasone Advair P O X 195 salmeterol/ fluticasone Advair P O X 61 nicotinic acid, extended release/ Advicor P P X lovastatin 195 flunisolide, inhaler Aerobid P P X 195 flunisolide, inhaler Aerobid M P P X 197 spacer Aerochamber P 3 P 3 X 20 amprenavir Agenerase P O X 34 aspirin/ dipyridamole Aggrenox P P X 34 anagrelide Agrylin O O HMSA DRUG FORMULARY - Listed alphabetically by BRAND name Rev.
    [Show full text]
  • Pharmacy Data Management Drug Exception List
    Pharmacy Data Management Drug Exception List Patch PSS*1*127 updated the following drugs with the listed NCPDP Multiplier and NCPDP Dispense Unit. These two fields were added as part of this patch to the DRUG file (#50). Please refer to the Release notes for ePharmacy/ECME Enhancements for Pharmacy Release Notes (BPS_1_5_EPHARMACY_RN_0907.PDF) on the VistA Documentation Library (VDL). The IEN column reflects the IEN for the VA PRODUCT file (#50.68). The ePharmacy Change Control Board provided the following list of drugs with the specified NCPDP Multiplier and NCPDP Dispense Unit values. This listing was used to update the DRUG file (#50) with a post install routine in the PSS*1*127 patch. NCPDP File 50.68 NCPDP Dispense IEN Product Name Multiplier Unit 2 ATROPINE SO4 0.4MG/ML INJ 1.00 ML 3 ATROPINE SO4 1% OINT,OPH 3.50 GM 6 ATROPINE SO4 1% SOLN,OPH 1.00 ML 7 ATROPINE SO4 0.5% OINT,OPH 3.50 GM 8 ATROPINE SO4 0.5% SOLN,OPH 1.00 ML 9 ATROPINE SO4 3% SOLN,OPH 1.00 ML 10 ATROPINE SO4 2% SOLN,OPH 1.00 ML 11 ATROPINE SO4 0.1MG/ML INJ 1.00 ML 12 ATROPINE SO4 0.05MG/ML INJ 1.00 ML 13 ATROPINE SO4 0.4MG/0.5ML INJ 1.00 ML 14 ATROPINE SO4 0.5MG/ML INJ 1.00 ML 15 ATROPINE SO4 1MG/ML INJ 1.00 ML 16 ATROPINE SO4 2MG/ML INJ 1.00 ML 18 ATROPINE SO4 2MG/0.7ML INJ 0.70 ML 21 ATROPINE SO4 0.3MG/ML INJ 1.00 ML 22 ATROPINE SO4 0.8MG/ML INJ 1.00 ML 23 ATROPINE SO4 0.1MG/ML INJ,SYRINGE,5ML 5.00 ML 24 ATROPINE SO4 0.1MG/ML INJ,SYRINGE,10ML 10.00 ML 25 ATROPINE SO4 1MG/ML INJ,AMP,1ML 1.00 ML 26 ATROPINE SO4 0.2MG/0.5ML INJ,AMP,0.5ML 0.50 ML 30 CODEINE PO4 30MG/ML
    [Show full text]
  • ABSTRACT This Material Provides Documentation for Users of the Micro-Data Files of the 2000 National Hospital Ambulatory Medical
    2000 NHAMCS MICRO-DATA FILE DOCUMENTATION PAGE 1 ABSTRACT This material provides documentation for users of the micro-data files of the 2000 National Hospital Ambulatory Medical Care Survey (NHAMCS). The NHAMCS is a national probability sample survey of visits to hospital outpatient and emergency departments, conducted by the National Center for Health Statistics, Centers for Disease Control and Prevention. The survey is a component of the National Health Care Survey, which measures health care utilization across a variety of health care providers. There are two micro-data files produced from the NHAMCS, one for outpatient department records and one for emergency department records. Section I of this documentation, “Description of the National Hospital Ambulatory Medical Care Survey,” includes information on the scope of the survey, the sample, field activities, data collection procedures, medical coding procedures, and population estimates. Section II provides detailed descriptions of the contents of each file’s data record by location. Section III contains marginal data for selected items on each file. The appendixes contain sampling errors, instructions and definitions for completing the Patient Record forms, and lists of codes used in the survey. PAGE 2 2000 NHAMCS MICRO-DATA FILE DOCUMENTATION THIS PAGE HAS BEEN LEFT BLANK INTENTIONALLY. 2000 NHAMCS MICRO-DATA FILE DOCUMENTATION PAGE 3 Table of Contents Page I. Description of the National Hospital Ambulatory Medical Care Survey A. Introduction ..........................................................5
    [Show full text]
  • BCBSNM/HMONM Therapeutic Class Drug List (Formulary) 2004
    BCBSNM/HMONM Therapeutic Class Drug List (Formulary) 2004 I. Antineoplastics and Immunosuppressants A. Antineoplastics B. Immunosuppressants II. Blood Modifiers A. Anticoagulants B. Platelet Aggregation Inhibitors C. Miscellaneous III. Cardiovascular Agents A. ACE Inhibitors B. Alpha Blockers C. Angiotensin II Receptor Blockers D. Antiarrhythmics and Cardiac Glycosides E. Beta Blockers F. Calcium Channel Blockers G. Diuretics H. Lipid Lowering Agents I. Nitrates J. Miscellaneous IV. Central Nervous System A. Alzheimer’s Disease B. Analgesics C. Migraine D. Parkinson’s Disease E. Seizures V. Dermatology A. Acne B. Bacterial Infections C. Corticosteroids D. Fungal Infections E. Psoriasis F. Scabies and Pediculosis G. Viral Infections H. Miscellaneous VI. Ear, Nose, and Throat A. Ear B. Nose C. Throat and Mouth Page 1 of 35 web\web documents\drug formularies\print formulary\print_tc_formulary_2004.doc BCBSNM / HMONM Therapeutic Class Drug List 2004 VII. Endocrinology A. Adrenal Corticosteroids B. Diabetes Mellitus C. Osteoporosis D. Paget's Disease E. Thyroid Modifiers F. Miscellaneous VIII. Gastrointestinal A. Diarrhea B. Emesis C. Inflammatory Bowel Disease D. Pancreatic Enzymes E. Reflux (GERD) F. Spasm G. Ulcers H. Miscellaneous IX. Infectious Diseases A. Antimicrobials B. Antifungals C. Antivirals D. Miscellaneous E. Web site reference X. Musculoskeletal A. Gout B. Rheumatoid and Osteoarthritis C. Skeletal Muscle Relaxants XI. OB-GYN A. Contraceptives B. Endometriosis C. Menopausal/Postmenopausal Symptoms D. Vaginal Infections E. Miscellaneous Page 2 of 35 web\web documents\drug formularies\print formulary\print_tc_formulary_2004.doc BCBSNM / HMONM Therapeutic Class Drug List 2004 XII. Ophthalmic A. Allergy B. Anti-inflammatories C. Infections D. Glaucoma E. Miscellaneous XIII. Psychiatric A. Alcohol Deterrents B.
    [Show full text]
  • Synergistic and Antagonistic Drug Interactions in the Treatment
    RESEARCH ARTICLE Synergistic and antagonistic drug interactions in the treatment of systemic fungal infections Morgan A Wambaugh, Steven T Denham, Magali Ayala, Brianna Brammer, Miekan A Stonhill, Jessica CS Brown* Division of Microbiology and Immunology, Pathology Department, University of Utah School of Medicine, Salt Lake City, United States Abstract Invasive fungal infections cause 1.6 million deaths annually, primarily in immunocompromised individuals. Mortality rates are as high as 90% due to limited treatments. The azole class antifungal, fluconazole, is widely available and has multi-species activity but only inhibits growth instead of killing fungal cells, necessitating long treatments. To improve treatment, we used our novel high-throughput method, the overlap2 method (O2M) to identify drugs that interact with fluconazole, either increasing or decreasing efficacy. We identified 40 molecules that act synergistically (amplify activity) and 19 molecules that act antagonistically (decrease efficacy) when combined with fluconazole. We found that critical frontline beta-lactam antibiotics antagonize fluconazole activity. A promising fluconazole-synergizing anticholinergic drug, dicyclomine, increases fungal cell permeability and inhibits nutrient intake when combined with fluconazole. In vivo, this combination doubled the time-to-endpoint of mice with Cryptococcus neoformans meningitis. Thus, our ability to rapidly identify synergistic and antagonistic drug interactions can potentially alter the patient outcomes. *For correspondence: Introduction [email protected] Invasive fungal infections are an increasing problem worldwide, contributing to 1.6 million deaths annually (Almeida et al., 2019; Bongomin et al., 2017; Brown et al., 2012). These problematic Competing interests: The infections are difficult to treat for many reasons. Delayed diagnoses, the paucity and toxicity of anti- authors declare that no fungal drugs, and the already immunocompromised state of many patients result in mortality rates competing interests exist.
    [Show full text]